Zydus Lifesciences is preparing to launch Semaglutide injection under the brand names SEMAGLYN, MASHEMA and ALTERME, following the patent expiry of the molecule in the country. The Drug Controller General of India (DCGI) has already granted approval for the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and obesity, […]